Abstract
Immunization of mice with dendritic cells transfected ex vivo with tumor-associated antigen (TAA)-encoding mRNA primes cytotoxic T lymphocytes (CTL) that mediate tumor rejection. Here we investigated whether direct injection of TAA mRNA, encapsulated in cationic liposomes, could function similarly as cancer immunotherapy. Intradermal and intravenous injection of ovalbumin (OVA) mRNA generated specific CTL activity and inhibited the growth of OVA-expressing tumors. Vaccination studies with DNA have demonstrated that co-administration of antigen (Ag)- and cytokine-encoding plasmids potentiate the T cell response; in analogous fashion, the inclusion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mRNA enhanced OVA-specific cytotoxicity. The ability of this GM-CSF-augmented mRNA vaccine to treat an established spontaneous tumor was evaluated in the Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) mouse, using the SV40 large T Ag (TAg) as a model tumor/self Ag. Repeated vaccination elicited vigorous TAg-specific CTL activity in nontransgenic mice, but tumor-bearing TRAMP mice remained tolerant. Adoptive transfer of naïve splenocytes into TRAMP mice prior to the first vaccination restored TAg reactivity, and slowed tumor progression. The data from this study suggests that vaccination with TAA mRNA is a simple and effective means of priming antitumor CTL, and that immunogenicity of the vaccine can be augmented by co-delivery of GM-CSF mRNA. Nonetheless, limitations of such vaccines in overcoming tolerance to tumor/self Ag may mandate prior or simultaneous reconstitution of the autoreactive T cell repertoire for this form of immunization to be effective.
Similar content being viewed by others
Abbreviations
- Ag:
-
Antigen
- APCs:
-
Antigen-presenting cells
- AT:
-
Adoptive transfer
- BMDC:
-
Bone marrow-derived dendritic cells
- CaP:
-
Prostate carcinoma
- CTL:
-
Cytotoxic T lymphocyte
- CTLA-4:
-
Cytotoxic T lymphocyte antigen-4
- E:T:
-
Effector: target
- GFP:
-
Green fluorescent protein
- GM-CSF:
-
Granulocyte-macrophage colony-stimulating factor
- GMTV:
-
Gene-modified tumor vaccine
- HA:
-
Hemagglutinin
- ID:
-
Intradermal
- IL:
-
Interleukin
- IV:
-
Intravenous
- IVT:
-
In vitro transcribed
- OVA:
-
Ovalbumin
- pDNA:
-
Plasmid DNA
- PI:
-
Postinjection
- PIN:
-
Prostatic intraepithelial neoplasia
- PSA:
-
Prostate-specific antigen
- SQ:
-
Subcutaneous
- TAA:
-
Tumor-associated antigen
- TAg:
-
SV40 large T antigen
- TRAMP:
-
Transgenic adenocarcinoma of mouse prostate
- wt:
-
Wild type
References
Iezzi G, Karjalainen K, Lanzavecchia A (1998) The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 8:89–95
van Stipdonk MJB, Hardenberg G, Bijker M, Lemmens EE, Droin NM, Green DR, Schoenberger SP (2003) Dynamic programming of CD8+ T lymphocyte responses. Nat Immunol 4:361–365
Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, Vieweg J, Gilboa E (2000) Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 6:1011–1017
Boczkowski D, Nair SK, Synder D, Gilboa E (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184:465–472
Martinon F, Krishnan S, Lenzen G, Magne R, Gomard E, Guillet J-G, Levy J-P, Meulien P (1993) Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol 23:1719–1722
Hoerr I, Obst R, Rammensee H-G, Jung G (2000) In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 30:1–7
Zhou W-Z, Hoon DSB, Huang SKS, Fujii S, Hashimoto K, Morishita R, Kaneda Y (1999) RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization. Hum Gene Ther 10:2719–2724
Ying H, Zaks TZ, Wang R-F, Irvine KR, Kammula US, Marincola FM, Leitner WW, Restifo NP (1999) Cancer therapy using a self-replicating RNA vaccine. Nat Med 5:823–827
Schirrmacher V, Forg P, Dalemans W, Chlichlia K, Zeng Y, Fournier P, von Hoegen P (2000) Intra-pinna anti-tumor vaccination with self-replicating infectious RNA or with DNA encoding a model tumor antigen and a cytokine. Gene Ther 7:1137–1147
Colmenero P, Liljestrom P, Jondal M (1999) Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene. Gene Ther 6:1728–1733
Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M, Wu TC (2001) Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. J Virol 75:2368–2376
Ishii N, Fukushima J, Kaneko T, Okada E, Tani K, Tanaka S-I, Hamajima K, Xin K-Q, Kawamoto S, Koff WC (1997) Cationic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1. AIDS Res Hum Retrovir 13:1421–1427
Li X-L, Boyanapalli M, Weihua X, Kalvakolanu DV, Hassel BA (1998) Induction of interferon synthesis and activation of interferon-stimulated genes by liposomal transfection reagents. J Interferon Cytokine Res 18:947–952
Xiang Z, Ertl HC (1995) Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 2:129–135
Iwasaki A, Stiernholm BJ, Chan AK, Berinstein NL, Barber BH (1997) Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol 158:4591–4601
Geissler M, Gesien A, Tokushige K, Wands JR (1997) Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol 158:1231–1237
Charo J, Ciupitu AM, Le Chevalier De Preville A, Trivedi P, Klein G, Hinkula J, Kiessling R (1999) A long-term memory obtained by genetic immunization results in full protection from a mammary adenocarcinoma expressing an EBV gene. J Immunol 163:5913–5919
Bowne WB, Srinivasan R, Wolchok JD, Hawkins WG, Blachere NE, Dyall R, Lewis JJ, Houghton AN (1999) Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 190:1711–1722
Gabrilovich EI, Ciernik IF, Carbone DP (1996) Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol 170:101–110
Bronte V, Chappelli DB, Appoloni E, Cabrelle A, Wang M, Hwu P, Restifo NP (1999) Unopposed production of granulocyte-macrophage colony stimulating factor by tumors inhibits CD8+ T cell response by dysregulating antigen-presenting cell maturation. J Immunol 162:5278–5283
Mizoguchi H, O’Shea JJ, Longo DL, Loefller CM, McVicar DW, Ochoa AC (1992) Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258:1795–1798
Kolenko V, Wang Q, Riedy MC, O’Shea J, Ritz J, Cathcart MK, Rayman P, Tubbs R, Edinger M, Novick A et al. (1997) Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas. J Immunol 159:3057–3067
Correa MR, Ochoa AC, Ghosh P, Mizoguchi H, Harvey L, Longo DL (1997) Sequential development of structural and functional alterations in T cells from tumor-bearing mice. J Immunol 158:5292–5296
Dyall R, Bowne WB, Weber LW, LeMaoult J, Szabo P, Moroi Y, Piskun G, Lewis JJ, Houghton AN, Nikolic-Zugic J (1998) Heteroclitic immunization induces tumor immunity. J Exp Med 188:1553–1561
Tsuboi A, Oka Y, Ogawa H, Elisseeva OA, Li H, Kawasaki K, Aozasa K, Kishimoto T, Udaka K, Sugiyama H (2000) Cytotoxic T-lymphocyte responses elicited to Wilms’ tumor gene WT1 product by DNA vaccination. J Clin Immunol 20:195–202
Bronte V, Apolloni E, Ronca R, Zamboni P, Overwijk WW, Surman DR, Restifo NP, Zanovello P (2000) Genetic vaccination with “self” tyrosinase-related protein 2 causes melanoma eradication but not vitilligo. Canc Res 60:253–258
Tuting T, Bambotto A, De Leo A, Lotze MT, Robbins PD, Storkus WJ (1999) Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Canc Gene Ther 6:73–80
Greenberg NM, DeMayo F, Finegold MH, Medina D, Tilley WD, Aspinal JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM (1995) Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92:3439–3443
Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MH, Angelopoulou R, Rosen JM, Greenberg NM (1996) Metastatic prostate cancer in a transgenic mouse. Canc Res 56:4096–4102
Granziero L, Krajewski S, Farness P, Yuan L, Courtney MK, Jackson MR, Peterson PA, Vitiello A (1999) Adoptive immunotherapy prevents prostate cancer in a transgenic animal model. Eur J Immunol 29:1127–1138
Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP (2000) Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Canc Res 60:2444–2448
Mandleboim O, Berke G, Fridkin M, Feldman M, Eisenstein M, Eisenbach L (1994) CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature 369:67–71
Mylin LM, Deckhut AM, Bonneau RH, Kierstead TD, Tevethia MJ, Simmons DT, Tevethia SS (1995) Cytotoxic T lymphoctye escape variants, induced mutations, and synthetic peptides define a dominant H2-Kb-restricted determinant in simian virus 40 tumor antigen. Virology 208:159–17 2
Rock KL, Rothstein L, Gamble S (1990) Generation of class I MHC-restricted T-T hybridomas. J Immunol 145:804–811
Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM (1997) Androgen-independent prostate cancer progression in the TRAMP model. Canc Res 57:4687–491
Lu D, Benjamin R, Kim M, Conry RM, Curiel DT (1994) Optimization of methods to achieve mRNA-mediated transfection of tumor cells in vitro and in vivo employing cationic liposome vectors. Canc Gene Ther 1:245–252
Speiser DE, Miranda R, Zakarian A, Bachman MF, McKall-Faienza K, Odermatt B, Hanahan D, Zinkernagel RM, Ohashi PS (1997) Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med 186:645–653
Grossmann ME, Davila E, Celis E (2001) Avoiding tolerance against prostatic antigens with subdominant peptide epitopes. J Immunother 24:237–241
Schell TD, Knowles BB, Tevethia SS (2000) Sequential loss of cytotoxic T lymphocyte responses to simian virus 40 large T antigen epitopes in T antigen transgenic mice developing osteosarcomas. Canc Res 60:3002–3012
Mounkes LC, Zhong W, Cipres-Palacin G, Heath TD, Debs RJ (1998) Proteoglycans mediate cationic liposome-DNA complex-based gene delivery in vitro and in vivo. J Biol Chem 273:26164–26170
Farhood H, Serbina N, Huang L (1995) The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochem Biophys Acta 1235:289–295
Segal AW, Wills EJ, Richmond JE, Slavin G, Black CDV, Gregoriadis G (1974) Morphological observations on the cellular and subcellular destination of intravenously administered liposomes. Brit J Exp Path 55:320–326
Haddad D, Ramprakash J, Sedegah M, Charoenvit Y, Baumgartner T, Kumar S, Hoffman SL, Weiss WR (2000) Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. J Immunol 165:3772–3781
Bowne WB, Wolchok JD, Hawkins WG, Srinivasan R, Gregor P, Blachere NE, Moroi Y, Engelhorn ME, Houghton AN, Lewis JJ (1999) Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects. Cytokines Cell Mol Ther 5:217–225
Kim JJ, Trivedi NN, Nottingham LK, Morrison L, Tsai A, Hu Y, Mahalingam S, Dang K, Ahn L, Doyle NK, et al. (1998) Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur J Immunol 28:1089–1103
Kim JJ, Bagarazzi ML, Trivedi N, Hu Y, Kazahaya K, Wilson DM, Ciccarelli R, Chattergoon MA, Dang K, Mahalingam S et al. (1997) Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nat Biotech 15:641–646
Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539–3543
Soo Hoo W, Lundeen KA, Kohrumel JR, Pham N-L, Brostoff SW, Bartholomew RM, Carlo DJ (1999) Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model. J Immunol 162:7343–7349
Heiser A, Maurice MA, Yancey DR, Wu NZ, Dahm P, Pruitt SK, Boczkowski D, Nair SK, Ballo MS, Gilboa E, et al. (2001) Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol 166:2593–2960
Ludewig B, Ochsenbein AF, Odermatt F, Paulin D, Hengartner H, Zinkernagel RM (2000) Immunotherapy with dendritic cells directed against tumor antigen shared with normal host cells results in severe autoimmune disease. J Exp Med 191:795–803
Kass E, Schlom J, Thompson J, Guadagni F, Graziano P, Greiner JW (1999) Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Canc Res 59:676–683
Limmer A, Sacher T, Alferink J, Kretschmar M, Schonrich G, Nichterlein T, Arnold B, Hammerling GJ (1998) Failure to induce organ-specific autoimmunity by breaking of tolerance: importance of the microenvironment. Eur J Immunol 28:2395–2406
Morgan DJ, Kreuwel HTC, Fleck S, Levitsky HI, Pardoll DM, Sherman LA (1998) Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol 160:643–651
Eck SC, Turka LA (2001) Adoptive transfer enables tumor rejection targeted against a self-antigen without the induction of autoimmunity. Canc Res 61:3077–3083
Wei C, Willis RA, Tilton BR, Looney RJ, Lord EM, Barth RK, Frelinger JG (1997) Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy. Proc Natl Acad Sci USA 94:6369–6374
Heiser A, Dahm P, Yancey DR, Maurice MA, Boczkowski D, Nair SK, Gilboa E, Vieweg J (2000) Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol 164:5508–5514
Zheng X, Gao J-X, Zhang H, Geiger TL, Liu Y, Zheng P (2002) Clonal deletion of simian virus 40 large T antigen-specific T cells in the transgenic adenocarcinoma of mouse prostate mice: an important role for clonal deletion in shaping the repertoire of T cells specific for antigens overexpressed in solid tumors. J Immunol 169:4761–4769
Morgan RA, Dudley ME, Yu YYL, Zheng Z, Robbins PF, Theoret MR, Wunderlich JR, Hughes MS, Restifo NP, Rosenberg SA (2003) High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol 171:3287–3295
Kessels HW, Wolkers MC, van den Boom MD, van der Valk MA, Schumacher TN (2001) Immunotherapy through TCR gene transfer. Nat Immunol 2:957–961
Acknowledgments
We are grateful to Duane Mitchell, Brenda Faiola, Carmen Wong, Charu Adlakha, Justin Hart, and Catherine McLaughlin. We also thank Erning Li for help with statistical analysis, and Xu Lin, Barbara Foster, and Norman Greenberg for their assistance with the TRAMP mouse model.
Author information
Authors and Affiliations
Corresponding author
Additional information
Eli Gilboa was supported in part by National Institutes of Health grants RO1-CA-85307 and RO1-CA-89536.
Rights and permissions
About this article
Cite this article
Hess, P.R., Boczkowski, D., Nair, S.K. et al. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. Cancer Immunol Immunother 55, 672–683 (2006). https://doi.org/10.1007/s00262-005-0064-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-005-0064-z